Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical AB’s Year-end report 2023
Regulatory
Full year sales at upper end of financial guidance and an exciting year ahead
Invitation to presentation of Sedana Medical’s fourth quarter and year-end report for 2023
Non-regulatory
Sedana Medical AB (publ) plans to present its fourth quarter and year-end report for 2023 on Thursda…
Sedana Medical files submission for paediatric indication
Non-regulatory
Sedana Medical AB (publ) announces that the company has submitted a Type II variation with the aim o…
Financial Calendar
Year-End Report 2023 | 15 February 2024 | 07:00 |
Annual Report 2023 | 15 April 2024 | 16:00 |